(Q28296482)

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Randomized trials, generalizability, and meta-analysis: graphical insights for binary outcomes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Quantifying heterogeneity in a meta-analysis

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2007.02427.X

Meta-analysis in clinical trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Malignancy, thrombosis and Trousseau: the case for an eponym.

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Coagulation proteases and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Tissue factor, thrombin, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Antitumor and antimetastatic effect of warfarin and heparins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Heparin and chemotherapy in the management of inoperable lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

CANCER INCIDENCE AND MORTALITY IN PATIENTS HAVING ANTICOAGULANT THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Allocation concealment in randomised trials: defending against deciphering

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Odds ratios should be avoided when events are common

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Current controversies in the application of meta-analysis (with special reference to oncological treatments)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X

The MET oncogene drives a genetic programme linking cancer to haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2007.02427.X